Galderma Group AG (BMV:GALD.N)
Mexico · Delayed Price · Currency is MXN | Market Cap | 1.03T +27.5% |
| Revenue (ttm) | 103.49B +26.3% |
| Net Income | 15.08B +128.3% |
| EPS | 67.30 +129.8% |
| Shares Out | n/a |
| PE Ratio | 62.35 |
| Forward PE | 40.38 |
| Dividend | 7.74 (0.18%) |
| Ex-Dividend Date | Apr 24, 2026 |
| Volume | 548 |
| Open | 4,195.64 |
| Previous Close | n/a |
| Day's Range | 4,195.64 - 4,195.64 |
| 52-Week Range | 3,212.38 - 4,195.64 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Feb 25, 2027 |
About Galderma Group AG
Galderma Group AG operates as a dermatology company worldwide. The company delivers a science-based portfolio of brands and services for the dermatology market, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. Its portfolio of flagship brands includes Azzalure, ALLUZIENCE, Dysport, Restylane, Restylane Skinboosters, Sculptra, Cetaphil, ALASTIN, Soolantra, Epiduo, Epiduo Forte, Differin, AKLIEF, Oracea, Metvix, NEMLUVIO, Relfydess, Benzac, and Loceryl in therapeutic dermatology. The company was founded in 19... [Read more]
Financial Performance
In 2025, Galderma Group AG's revenue was $5.24 billion, an increase of 18.04% compared to the previous year's $4.44 billion. Earnings were $613.00 million, an increase of 165.37%.
Financial numbers in USD Financial StatementsNews
Galderma launches ALASTIN Restorative Eye Complex with TriHex+™, bringing new science-backed innovation to the entire eye area
Restorative Eye Complex is now formulated with TriHex+™, which pairs ALASTIN's TriHex Technology® to support the body's natural processes for collagen and elastin production with proprietary Octapepti...
Galderma's Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) today announced that the Chinese NMPA has approved Relfydess for the temporary improvement of moderate-to-severe frown lines in adults, marking ...
Galderma Group AG Earnings Call Transcript: Q3 2026
9M sales reached $4.765B, up 25.1% CC, prompting higher FY growth guidance while Core EBITDA margin guidance stayed at ~26%. ZO Skin Health adds a strategic skincare platform, with renewed growth targeted from 2028.
Galderma Group AG Earnings release: Q3 2026
Galderma Group AG released its Q3 2026 earnings on October 22, 2026, summarizing the period's financial results.
Galderma Group AG Slides: Q3 2026
Galderma Group AG has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 22, 2026.
Ozempic, Botox and the anti-aging boom: Galderma CEO on what's driving beauty spending
Galderma CEO, Flemming Ørnskov, discusses the impact of GLP-1 drugs on demand for the company's products.
Galderma Q3 Sales Climb; Confirms FY26 Core EBITDA Margin View, Lifts Sales Growth Outlook; Stock Up
(RTTNews) - Galderma Group AG (GALD.SW, GALDY), a Swiss pharmaceutical company, reported Thursday strong growth in third-quarter sales, with broad-based double-digit growth across geographies and prod...
Galderma lifts outlook for second quarter in a row after sales jump
Swiss skincare company Galderma raised its full-year sales guidance on Thursday for the second time in two quarters after strong demand for its therapeutic dermatology products drove robust growth i...
Galderma Delivers Net Sales of 4.765 B USD in the First Nine Months, Up 25.1% at Constant Currency Year-on-Year, and Raises Full-Year Net Sales Guidance
ZUG, Switzerland--(BUSINESS WIRE)--Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first nine months of 2026. Record net sales of...
AMWC Dubai 2026: Galderma Reinforces Its Injectable Aesthetics Leadership
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) will showcase data from its leading innovative Injectable Aesthetics portfolio at the Aesthetic & Anti-Aging Medicine World Congress (AMWC) taki...
Galderma Reports Sustained Nemolizumab Benefits In Children With Atopic Dermatitis
(RTTNews) - Thursday, Galderma Group AG (GDERF) reported new Phase 2 data showing sustained improvements in itch, sleep disturbance, and quality of life through Week 52 with nemolizumab in children ag...
Galderma to Buy ZO Skin Health for $1.5 Billion
The dermatology company agreed to acquire ZO Skin Health from its shareholders, including the Obagi family and funds managed by Blackstone Tactical Opportunities.
Galderma To Acquire ZO Skin Health For $1.5 Bln
(RTTNews) - Galderma Group AG (GALD.SW, GALDY), a Swiss pharmaceutical company, on Wednesday announced that it has agreed to acquire ZO Skin Health from Blackstone Inc. (BX) for an enterprise value of...
Galderma Signs Agreement to Acquire ZO Skin Health, Strengthening Its Physician-Dispensed Skincare Offering
ZUG, Switzerland & IRVINE, Calif.--(BUSINESS WIRE)--Galderma (SIX: GALD) today announced that it has signed an agreement to acquire ZO® Skin Health, a leading physician-dispensed skincare brand built ...
New Galderma Research Reveals More Than Half of Women Mistake Menopause-Related Skin Changes for Signs of Ageing
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) today announced new global research revealing that more than half (56%) of women first put menopause-related skin changes down to general ageing...
Fall Clinical 2026: Galderma Presents New Three-Year Nemluvio® Data Showing Deep and Lasting Skin Lesion and Itch Responses in Patients With Atopic Dermatitis Aged 12 and Older
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, today announced new data regarding the use of Nemluvio for atopic dermatitis and prurigo nodularis t...
Galderma Highlights Recent Restylane Approvals At 30-Year Mark
(RTTNews) - Galderma Group AG (GALD.SW, GDERF) announced that its Restylane injectable aesthetic product line has reached its 30th anniversary since its European launch. Restylane, which was introduce...
EADV 2026: Galderma's New Data Show Sustained Improvements with Nemluvio® (nemolizumab) for up to Three Years in Patients With Moderate-to-severe Atopic Dermatitis
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, is presenting new three-year data from the ARCADIA long-term extension study, demonstrating that Nem...
EADV 2026: Galderma to Unveil New Data Advancing Understanding of Skin Diseases, Skin Longevity, and Real-world Patient Experiences
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD), the pure-play dermatology category leader, will present 19 abstracts and deliver a broad scientific education program at the 2026 European Acad...
Galderma mindful of focus while eyeing product range expansion, CEO tells FuW
Galderma's CEO said the Swiss skincare firm plans to expand its product range at some point but would remain cautious not to lose its focus, speaking in an interview with Swiss newspaper Finanz und...
Galderma's Restylane® Volyme™ Demonstrates High Effectiveness, Satisfaction and a Robust Safety Profile in Chinese Patients With Temple Hollowing
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) today announced positive topline results from a study of Restylane Volyme for the correction of moderate-to-severe temple hollowing in 162 patie...
Plastic surgery is booming with boomers. Here's how to cash in on the antiaging craze.
Americans age 65 and older are suddenly the fastest-growing customers for cosmetic surgery.
Galderma Receives European Union Approval for Restylane® Shaype™: the First-and-Only Bone-Mimicking Hyaluronic Acid Injectable for Facial Shaping
ZUG, Switzerland--(BUSINESS WIRE)--Galderma (SIX: GALD) today announced that Restylane Shaype has been approved in the EU under the Medical Device Regulation for temporary augmentation of the chin reg...
Galderma Group AG Earnings Call Transcript: Q2 2026
Record H1 2026 net sales of $3.1B, up 24.6% year-on-year, with strong double-digit growth across all segments and geographies. Core EBITDA margin expanded to 25.6%, and full-year guidance was raised to 19%-21% net sales growth, with Nemluvio on track for $1B in sales.
Galderma Group AG Earnings release: Q2 2026
Galderma Group AG released its Q2 2026 earnings on July 23, 2026, summarizing the period's financial results.